Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,142.47
    +63.61 (+0.79%)
     
  • Bitcoin USD

    64,039.05
    +540.32 (+0.85%)
     
  • CMC Crypto 200

    1,339.16
    -57.37 (-4.10%)
     
  • S&P 500

    5,098.89
    +50.47 (+1.00%)
     
  • Dow

    38,207.11
    +121.31 (+0.32%)
     
  • Nasdaq

    15,909.07
    +297.31 (+1.90%)
     
  • Gold

    2,347.10
    +4.60 (+0.20%)
     
  • Crude Oil

    83.51
    -0.06 (-0.07%)
     
  • 10-Yr Bond

    4.6530
    -0.0530 (-1.13%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?

Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?

Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.